Status:

RECRUITING

China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project

Lead Sponsor:

Peking University First Hospital

Conditions:

Atopic Dermatitis Eczema

Prurigo Nodularis

Eligibility:

All Genders

Brief Summary

In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and t...

Eligibility Criteria

Inclusion

  • Patients from the medical units that has passed the data review of the National Clinical Center for Skin and Immune Diseases (see the study sites for data collection for details);
  • patients diagnosed with type 2 inflammatory skin diseases (dermatitis/eczema, urticaria, pemphigoid, prurigo nodularis).

Exclusion

  • patients who fail to provide informed consent form;
  • patients who cannot complete the questionnaire independently or under the guidance of investigators

Key Trial Info

Start Date :

August 31 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2031

Estimated Enrollment :

100000 Patients enrolled

Trial Details

Trial ID

NCT05316805

Start Date

August 31 2021

End Date

December 31 2031

Last Update

August 15 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking University First Hospital

Beijing, China

China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project | DecenTrialz